The preclinical data is supportive but early-stage and non-GLP. The critical near-term catalyst is the company's ability to secure financing given the minimal cash runway. Monitor for equity or debt offerings, partnership announcements, or IND-enabling study updates.
Price Chart
Executive Summary
Alaunos Therapeutics announced new preclinical statistical analysis for ALN1003, showing lower liver weight after adjusting for body fat percentage in a 48-day DIO mouse study. The data is directionally consistent with prior liver marker and biomarker findings, but remains non-GLP preclinical with no human trials. The company had only ~$0.354M cash as of March 31, 2026, and will need additional financing to continue development.
Key Facts
- ALN1003-treated animals showed lower liver weight after adjustment for body fat percentage (ANCOVA p=0.000005; HC3 robust p=0.000015) in a 48-day DIO mouse study.
- Findings are directionally consistent with previously disclosed lower liver injury enzymes, lower NAFLD Activity Scores (NAS), lower HOMA-IR, and favorable adipose endocrine biomarkers.
- ALN1003 has not been evaluated in human clinical trials; safety and efficacy in humans not established.
- As of March 31, 2026, the company had cash and cash equivalents of approximately $0.354 million and intends to pursue additional financing.
- Data is from non-GLP preclinical studies with limitations including small sample sizes, post hoc analysis, and indirect liver weight measures.
Financial Impact
No revenue or material financial impact. Cash position of ~$0.354M as of March 31, 2026, necessitates near-term financing for continued operations.
Risk Factors
- Cash runway is extremely limited (~$0.354M) and the company will likely need to raise capital imminently, causing dilution.
- Preclinical mouse data may not translate to human clinical outcomes; ALN1003 has not been tested in humans.
- Non-GLP study limitations and post hoc analysis reduce the reliability of the findings.
- Competition in the obesity/metabolic disease space is intense, with many well-funded players.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-286914 |
| Document: tcrt-ex99_1.htm | 0001193125-26-286914 |
| Document: 0001193125-26-286914-index-headers.html | 0001193125-26-286914 |
| Document: 0001193125-26-286914-index.html | 0001193125-26-286914 |
| Document: 0001193125-26-286914.txt | 0001193125-26-286914 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 29, 2026 13w ago | 8-K | $2.37 $1.27 | ▼ −46.41% | ▼ −50.80% | $0.8840 (−62.70%) |
May 26, 2026 18w ago | 8-K | $2.45 $1.88 | ▲ +23.27% | ▲ +25.99% | $0.8840 (+63.92%) |
Apr 15, 2026 24w ago | 8-K | $2.83 $2.08 | ▲ +26.36% | ▲ +33.41% | $0.8840 (+68.76%) |
Mar 2, 2026 30w ago | Press Release | $3.32 $2.45 | ▼ −26.20% | ▼ −35.53% | $0.8840 (−73.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access